These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 39029053)

  • 1. The effect of early versus late remdesivir treatment in hospitalized mild to moderate COVID-19 patients in the Omicron era: A retrospective study.
    Ryu BH; Lee JY; Lee SH
    Medicine (Baltimore); 2024 Jul; 103(29):e39035. PubMed ID: 39029053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of early remdesivir administration in COVID-19 disease progression in hospitalised patients.
    Platzer M; Totschnig D; Karolyi M; Clodi-Seitz T; Wenisch C; Zoufaly A
    Wien Klin Wochenschr; 2024 Aug; 136(15-16):458-464. PubMed ID: 38884783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early administration of remdesivir to COVID-19 patients associates with higher recovery rate and lower need for ICU admission: A retrospective cohort study.
    Hussain Alsayed HA; Saheb Sharif-Askari F; Saheb Sharif-Askari N; Hussain AAS; Hamid Q; Halwani R
    PLoS One; 2021; 16(10):e0258643. PubMed ID: 34699552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world evaluation of early remdesivir in high-risk COVID-19 outpatients during Omicron including BQ.1/BQ.1.1/XBB.1.5.
    Molina KC; Webb BJ; Kennerley V; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Peers JL; Russell S; Wynia MK; Aggarwal NR; Ginde AA
    BMC Infect Dis; 2024 Aug; 24(1):802. PubMed ID: 39118052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
    Spinner CD; Gottlieb RL; Criner GJ; Arribas López JR; Cattelan AM; Soriano Viladomiu A; Ogbuagu O; Malhotra P; Mullane KM; Castagna A; Chai LYA; Roestenberg M; Tsang OTY; Bernasconi E; Le Turnier P; Chang SC; SenGupta D; Hyland RH; Osinusi AO; Cao H; Blair C; Wang H; Gaggar A; Brainard DM; McPhail MJ; Bhagani S; Ahn MY; Sanyal AJ; Huhn G; Marty FM;
    JAMA; 2020 Sep; 324(11):1048-1057. PubMed ID: 32821939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19.
    Garibaldi BT; Wang K; Robinson ML; Zeger SL; Bandeen-Roche K; Wang MC; Alexander GC; Gupta A; Bollinger R; Xu Y
    JAMA Netw Open; 2021 Mar; 4(3):e213071. PubMed ID: 33760094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.
    Gottlieb RL; Vaca CE; Paredes R; Mera J; Webb BJ; Perez G; Oguchi G; Ryan P; Nielsen BU; Brown M; Hidalgo A; Sachdeva Y; Mittal S; Osiyemi O; Skarbinski J; Juneja K; Hyland RH; Osinusi A; Chen S; Camus G; Abdelghany M; Davies S; Behenna-Renton N; Duff F; Marty FM; Katz MJ; Ginde AA; Brown SM; Schiffer JT; Hill JA;
    N Engl J Med; 2022 Jan; 386(4):305-315. PubMed ID: 34937145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remdesivir for the Treatment of Covid-19 - Final Report.
    Beigel JH; Tomashek KM; Dodd LE; Mehta AK; Zingman BS; Kalil AC; Hohmann E; Chu HY; Luetkemeyer A; Kline S; Lopez de Castilla D; Finberg RW; Dierberg K; Tapson V; Hsieh L; Patterson TF; Paredes R; Sweeney DA; Short WR; Touloumi G; Lye DC; Ohmagari N; Oh MD; Ruiz-Palacios GM; Benfield T; Fätkenheuer G; Kortepeter MG; Atmar RL; Creech CB; Lundgren J; Babiker AG; Pett S; Neaton JD; Burgess TH; Bonnett T; Green M; Makowski M; Osinusi A; Nayak S; Lane HC;
    N Engl J Med; 2020 Nov; 383(19):1813-1826. PubMed ID: 32445440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19.
    Ohl ME; Miller DR; Lund BC; Kobayashi T; Richardson Miell K; Beck BF; Alexander B; Crothers K; Vaughan Sarrazin MS
    JAMA Netw Open; 2021 Jul; 4(7):e2114741. PubMed ID: 34264329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remdesivir for the Treatment of Severe COVID-19: A Community Hospital's Experience.
    Lee S; Santarelli A; Caine K; Schritter S; Dietrich T; Ashurst J
    J Am Osteopath Assoc; 2020 Dec; 120(12):926-933. PubMed ID: 33136164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed Initiation of Remdesivir in a COVID-19-Positive Patient.
    Hillaker E; Belfer JJ; Bondici A; Murad H; Dumkow LE
    Pharmacotherapy; 2020 Jun; 40(6):592-598. PubMed ID: 32281114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended remdesivir administration in haematological patients with malignancies and COVID-19 during the Omicron era: safety and outcomes.
    Gras E; Aiello TF; Chumbita M; Gallardo-Pizarro A; Monzó-Gallo P; Teijón-Lumbreras C; Suárez-Lledó M; Magnano L; Tuset M; Marcos MÁ; Soriano A; Garcia-Vidal C
    J Antimicrob Chemother; 2024 Sep; 79(9):2364-2368. PubMed ID: 38985649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel.
    Goldberg E; Ben Zvi H; Sheena L; Sofer S; Krause I; Sklan EH; Shlomai A
    Clin Microbiol Infect; 2021 Jun; 27(6):917.e1-917.e4. PubMed ID: 33705849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and Virologic Effectiveness of Remdesivir Treatment for Severe Coronavirus Disease 2019 (COVID-19) in Korea: a Nationwide Multicenter Retrospective Cohort Study.
    Joo EJ; Ko JH; Kim SE; Kang SJ; Baek JH; Heo EY; Shi HJ; Eom JS; Choe PG; Bae S; Ra SH; Kim DY; Kim BN; Kang YM; Kim JY; Chung JW; Chang HH; Bae S; Cheon S; Park Y; Choi H; Lee E; Lee BY; Park JW; Sohn Y; Heo JY; Kim SH; Peck KR
    J Korean Med Sci; 2021 Mar; 36(11):e83. PubMed ID: 33754512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remdesivir (Veklury) for the Treatment of COVID-19 in Hospitalized Patients.
    Odeti S; Yellepeddi VK
    Am Fam Physician; 2021 Sep; 104(3):311-312. PubMed ID: 34523893
    [No Abstract]   [Full Text] [Related]  

  • 16. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
    Wang Y; Zhang D; Du G; Du R; Zhao J; Jin Y; Fu S; Gao L; Cheng Z; Lu Q; Hu Y; Luo G; Wang K; Lu Y; Li H; Wang S; Ruan S; Yang C; Mei C; Wang Y; Ding D; Wu F; Tang X; Ye X; Ye Y; Liu B; Yang J; Yin W; Wang A; Fan G; Zhou F; Liu Z; Gu X; Xu J; Shang L; Zhang Y; Cao L; Guo T; Wan Y; Qin H; Jiang Y; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
    Lancet; 2020 May; 395(10236):1569-1578. PubMed ID: 32423584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remdesivir for Adults With COVID-19 : A Living Systematic Review for American College of Physicians Practice Points.
    Wilt TJ; Kaka AS; MacDonald R; Greer N; Obley A; Duan-Porter W
    Ann Intern Med; 2021 Feb; 174(2):209-220. PubMed ID: 33017170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remdesivir in combination with dexamethasone for patients hospitalized with COVID-19: A retrospective multicenter study.
    Gressens SB; Esnault V; De Castro N; Sellier P; Sene D; Chantelot L; Hervier B; Delaugerre C; Chevret S; Molina JM;
    PLoS One; 2022; 17(2):e0262564. PubMed ID: 35176057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remdesivir as a broad-spectrum antiviral drug against COVID-19.
    Hong YN; Xu J; Sasa GBK; Zhou KX; Ding XF
    Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):541-548. PubMed ID: 33506946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A shorter symptom onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: A real-world analysis.
    Mehta RM; Bansal S; Bysani S; Kalpakam H
    Int J Infect Dis; 2021 May; 106():71-77. PubMed ID: 33647517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.